Abstract
During the COVID-19 pandemic, manufacturers have developed several diagnostic test kits that include lateral flow immunoassays (LFIA) also known as rapid cassette testing. Rapid cassette testing provides qualitative test results indicating the presence or absence of IgG and IgM antibodies to determine COVID-19 (SARS-CoV-2) infection among individuals. Venipuncture blood draws have been the traditional and widely proposed sample collection method but is costly and not applicable to point-of-care testing (POC) and in remote settings. Whole blood finger-stick blood collections traditionally used by diabetics for glucose level testing is an ideal scenario, but raises concerns regarding the outcome of test results in regards to specificity and sensitivity. In this study we directly compare simultaneous collections of venipuncture serum (SST) blood draws and whole blood finger-sticks (n = 75) to detect human Anti-COVID-19 IgG and IgM antibodies using an EUA-approved lateral flow immunoassay, showing equal to enhanced performance characteristics for this specimen type.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Alcala Pharmaceutical Inc. Institutional Review Board (IORG0010127) in consideration of the Code of Ethics of the World Medical Association (Declaration of Helsinki). All collection activities occurred at the phlebotomy collection site at Alcala Testing and Analysis Services or the San Diego Comprehensive Pain Management Clinic (SDCPMC), 3703 Camino del Rio South, San Diego, CA, 92108 by certified phlebotomists or licensed vocational nurses. Serum ELISA testing and comparison to rapid cassette results were conducted from 06/01/2020 to 07/27/2020 at Alcala Testing and Analysis Services. All subjects were recruited via phone or e-mail announcements with phone follow-up or by word of mouth at the San Diego Comprehensive Pain Management Clinic, 3703 Camino del Rio South, San Diego, CA, 92108. Healthcare workers from the clinic also volunteered. Healthcare workers or volunteers in any setting could enroll without a prior COVID-19 test. All specimens derived from human subjects were de-identified of their health information as defined by Health Insurance Portability and Accountability Act (HIPAA) guidelines. Seventy-five volunteers took part in a whole blood finger-stick collection with immediate application to the Healgen COVID-19 IgG and IgM antibody rapid cassette and a simultaneous venipuncture draw of serum (SST tiger top tube) analyzed by the EDI Novel Coronavirus COVID-19 IgG/IgM ELISA test procedure.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data related to volunteer testing is summarized in the manuscript and was deidentified according to HIPAA guidelines.
